<?xml version="1.0" encoding="UTF-8"?>
<p id="Par64">Of the patients with an objective response (BTH1677 
 <italic>n</italic> = 29; Control 
 <italic>n</italic> = 10), the median DOR was 10.3 months in the BTH1677 arm (95% CI: 5.6, not estimable) vs 5.6 months (95% CI: 1.5, not estimable) in the Control arm (HR 0.92 [95% CI: 0.27, 4.20]; 
 <italic>P</italic> = .9040; Table 
 <xref rid="Tab2" ref-type="table">2</xref> and Fig. 
 <xref rid="Fig4" ref-type="fig">4a</xref>). DOR by patient is illustrated in Fig. 
 <xref rid="Fig4" ref-type="fig">4b</xref>. Of the patients with progressive disease or death (BTH1677 
 <italic>n</italic> = 17; Control 
 <italic>n</italic> = 6), the PFS was 11.6 months in the BTH1677 arm and 9.6 months in the Control arm (HR 1.31 [95% CI: 0.54, 3.65]; 
 <italic>P</italic> = .5639; Table 
 <xref rid="Tab2" ref-type="table">2</xref>).
</p>
